June 2011 Latest GU Updates from ASCO

Published: Tue Jun 21, 2011 Updated:Wed Sep 14, 2011

We would like to thank Dr Lori Wood for the latest GU updates.

 

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial

A randomized phase III study comparing paclitaxel-BEP (T-BEP) to standard BEP in patients with intermediate prognosis germ cell cancer (GCC): An intergroup study of EORTC, German TCSG/AUO, MRC, and Spanish GCC group (EORTC 30983)

 

 

 

Sign-up for Our E-Newsletter